Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts

Phosphoinositide 3-kinases (PI3Ks) regulate several cellular functions that are critical for cancer progression and development, including cell survival, proliferation and migration. Three classes of PI3Ks exist with the class I PI3K encompassing four isoforms of the catalytic subunit known as p110α...

Full description

Bibliographic Details
Main Authors: Falasca, Marco, Maffucci, T.
Format: Journal Article
Published: Frontiers Media SA 2014
Subjects:
Online Access:http://hdl.handle.net/20.500.11937/44574
_version_ 1848757039611772928
author Falasca, Marco
Maffucci, T.
author_facet Falasca, Marco
Maffucci, T.
author_sort Falasca, Marco
building Curtin Institutional Repository
collection Online Access
description Phosphoinositide 3-kinases (PI3Ks) regulate several cellular functions that are critical for cancer progression and development, including cell survival, proliferation and migration. Three classes of PI3Ks exist with the class I PI3K encompassing four isoforms of the catalytic subunit known as p110α, p110β, p110γ, and p110δ. Although for many years attention has been mainly focused on p110α recent evidence supports the conclusion that p110β, p110γ, and p110δ can also have a role in cancer. Amongst these, accumulating evidence now indicates that p110γ is involved in several cellular processes associated with cancer and indeed this specific isoform has emerged as a novel important player in cancer progression. Studies from our laboratory have identified a specific overexpression of p110γ in human pancreatic ductal adenocarcinoma (PDAC) and in hepatocellular carcinoma (HCC) tissues compared to their normal counterparts.Our data have further established that selective inhibition of p110γ is able to block PDAC and HCC cell proliferation, strongly suggesting that pharmacological inhibition of this enzyme can directly affect growth of these tumors. Furthermore, increasing evidence suggests that p110γ plays also a key role in the interactions between cancer cells and tumor microenvironment and in particular in tumor-associated immune response. It has also been reported that p110γ can regulate invasion of myeloid cells into tumors and tumor angiogenesis. Finally p110γ has also been directly involved in regulation of cancer cell migration. Taken together these data indicate that p110γ plays multiple roles in regulation of several processes that are critical for tumor progression and metastasis. This review will discuss the role of p110γ in gastrointestinal tumor development and progression and how targeting this enzyme might represent a way to target very aggressive tumors such as pancreatic and liver cancer on multiple fronts.
first_indexed 2025-11-14T09:21:45Z
format Journal Article
id curtin-20.500.11937-44574
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T09:21:45Z
publishDate 2014
publisher Frontiers Media SA
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-445742018-04-09T05:07:33Z Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts Falasca, Marco Maffucci, T. 391 inflammation phosphoinositide3-kinase metastasis PDAC angiogenesis cancer HCC Phosphoinositide 3-kinases (PI3Ks) regulate several cellular functions that are critical for cancer progression and development, including cell survival, proliferation and migration. Three classes of PI3Ks exist with the class I PI3K encompassing four isoforms of the catalytic subunit known as p110α, p110β, p110γ, and p110δ. Although for many years attention has been mainly focused on p110α recent evidence supports the conclusion that p110β, p110γ, and p110δ can also have a role in cancer. Amongst these, accumulating evidence now indicates that p110γ is involved in several cellular processes associated with cancer and indeed this specific isoform has emerged as a novel important player in cancer progression. Studies from our laboratory have identified a specific overexpression of p110γ in human pancreatic ductal adenocarcinoma (PDAC) and in hepatocellular carcinoma (HCC) tissues compared to their normal counterparts.Our data have further established that selective inhibition of p110γ is able to block PDAC and HCC cell proliferation, strongly suggesting that pharmacological inhibition of this enzyme can directly affect growth of these tumors. Furthermore, increasing evidence suggests that p110γ plays also a key role in the interactions between cancer cells and tumor microenvironment and in particular in tumor-associated immune response. It has also been reported that p110γ can regulate invasion of myeloid cells into tumors and tumor angiogenesis. Finally p110γ has also been directly involved in regulation of cancer cell migration. Taken together these data indicate that p110γ plays multiple roles in regulation of several processes that are critical for tumor progression and metastasis. This review will discuss the role of p110γ in gastrointestinal tumor development and progression and how targeting this enzyme might represent a way to target very aggressive tumors such as pancreatic and liver cancer on multiple fronts. 2014 Journal Article http://hdl.handle.net/20.500.11937/44574 10.3389/fphys.2014.00391 http://creativecommons.org/licenses/by/4.0/ Frontiers Media SA fulltext
spellingShingle 391
inflammation
phosphoinositide3-kinase
metastasis
PDAC
angiogenesis
cancer
HCC
Falasca, Marco
Maffucci, T.
Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts
title Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts
title_full Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts
title_fullStr Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts
title_full_unstemmed Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts
title_short Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts
title_sort targeting p110gamma in gastrointestinal cancers: attack on multiple fronts
topic 391
inflammation
phosphoinositide3-kinase
metastasis
PDAC
angiogenesis
cancer
HCC
url http://hdl.handle.net/20.500.11937/44574